Psychotic disorders are characterized by high health and social burdens on those affected and their relatives. They are usually associated with social and job-related loss of function of the patients. This is associated with a significant reduction in the quality of life. At the same time, high financial costs are incurred for the health system. Despite all progress in treatment in recent decades, this situation has not improved significantly. Preventive measures are therefore currently considered to be the most promising therapeutic measures. Through a cooperative research project of the Universities of Cologne and Bonn, two new, preventive treatment approaches are now to be clinically tested.
The aim of the study is to reduce the transition rate of persons with an increased risk of disease to a diagnosed psychosis. The University of Cologne coordinates the module on "Integrated Preventive Psychological Intervention" (IPPI). This is a psychotherapeutic treatment approach. A second approach aims to prevent psychosis with the help of a well-tolerated antioxidant. This - in a lower dose obtainable without a prescription - drug is to develop its neuroprotective effect together with a psychotherapy, which is why the two therapies are tested together in a 6-month intervention phase.
Another study allows patients with schizophrenia to participate in one of two full-fledged psychotherapies over the course of half a year, focusing on restoring social functioning and cognitive abilities.
The research group ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments) aims to investigate new prevention and treatment approaches in schizophrenia. Schizophrenia is a brain disorder; It is caused by structural and biochemical changes in the brain and influences the perception of reality. It usually occurs in acute episodes, so-called schizophrenic episodes. Statistically, every hundredth person experiences a schizophrenic episode at least once in their lives.
Project researchers at the University Hospital Bonn:
Prof. Dr. Dr. René Hurlemann
Dr. Thomas Kinfe
Dr. Hanna Högenauer
M.Sc. Psych. Sven Wasserthal
Opportunities for study participation:
If you suffer from schizophrenia or symptoms that may indicate the presence of psychosis, we recommend that you make an appointment for an initial diagnosis with Mr. Sven Wasserthal (email@example.com / 0228/287 19740). Alternatively, you can find more information on our website http://www.psychose-frueherkennung.de/.